Abstract
Proteasome inhibitors, used in cancer treatment for their proapoptotic effects, have anti-inflammatory and antifibrotic effects on animal models of various inflammatory and fibrotic diseases. Their effects in cells from patients affected by either inflammatory or fibrotic diseases have been poorly investigated. Nasal polyposis is a chronic inflammatory disease of the sinus mucosa characterized by tissue inflammation and remodeling. We tested the hypothesis that proteasome inhibition of nasal polyp fibroblasts might reduce their proliferation and inflammatory and fibrotic response. Accordingly, we investigated the effect of the proteasome inhibitor Z-Leu-Leu-Leu-B(OH)2 (MG262) on cell viability and proliferation and on the production of collagen and inflammatory cytokines in nasal polyp and nasal mucosa fibroblasts obtained from surgery specimens. MG262 reduced the viability of nasal mucosa and polyp fibroblasts concentration- and time-dependently, with marked effects after 48 h of treatment. The proteasome inhibitor bortezomib provoked a similar effect. MG262-induced cell death involved loss of mitochondrial membrane potential, caspase-3 and poly(ADP-ribose) polymerase activation, induction of c-Jun phosphorylation, and mitogen-activated protein kinase phosphatase-1 expression. Low concentrations of MG262 provoked growth arrest, inhibited DNA replication and retinoblastoma phosphorylation, and increased expression of the cell cycle inhibitors p21 and p27. MG262 concentration-dependently inhibited basal and transforming growth factor-β-induced collagen mRNA expression and interleukin (IL)-1β-induced production of IL-6, IL-8, monocyte chemoattractant protein-1, regulated on activation normal T cell expressed and secreted, and granulocyte/macrophage colony-stimulating factor in both fibroblast types. MG262 inhibited IL-1β/tumor necrosis factor-α-induced activation of nuclear factor-κB. We conclude that noncytotoxic treatment with MG262 reduces the proliferative, fibrotic, and inflammatory response of nasal fibroblasts, whereas high MG262 concentrations induce apoptosis.
Footnotes
This work was supported by the Fondo de Investigación Sanitaria [Grant PI050057], Fundació La Marató de TV3 [Grant MTV3–040630], and FUCAP-Beca Maria Ravà 2008. The research activity of L.P. is supported by Instituto de Salud Carlos III-Fondo de Investigación Sanitaria.
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
↵ The online version of this article (available at http://jpet.aspetjournals.org) contains supplemental material.
ABBREVIATIONS:
- NF-κB
- nuclear factor-κB
- BMS-345541
- 4(2′-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline
- BSA
- bovine serum albumin
- CDK
- cyclin-dependent kinase
- DiOC6
- 3,3′-dihexyloxacarbocyanine iodide
- DMEM
- Dulbecco's modified Eagle's medium
- EdU
- 5-ethynyl-2′-deoxyuridine
- FACS
- fluorescence-activated cell sorting
- FBS
- fetal bovine serum
- csFBS
- charcoal-stripped FBS
- ELISA
- enzyme-linked immunosorbent assay
- GM-CSF
- granulocyte/macrophage colony-stimulating factor
- IKK
- IκB kinase
- IL
- interleukin
- JNK
- c-Jun-N-terminal kinase
- MAPK
- mitogen-activated protein kinase
- MKP-1
- MAPK phosphatase-1
- MCP-1
- monocyte chemoattractant protein-1
- MG132
- benzyloxycarbonylleucyl-leucyl-leucine aldehyde
- MG262
- Z-Leu-Leu-Leu-B(OH)2
- negC
- negative control
- NS
- not significant
- OD
- optical density
- PARP
- poly(ADP-ribose) polymerase
- PBS
- phosphate-buffered saline
- p-c-Jun
- phosphorylated c-Jun
- PCR
- polymerase chain reaction
- PPAR-γ
- peroxisome proliferator-activated receptor-γ
- RANTES
- regulated on activation normal T cell expressed and secreted
- Rb
- retinoblastoma
- p-Rb
- phosphorylated Rb
- siRNA
- small interfering RNA
- SB203580
- 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole
- SP1
- specificity protein 1
- SP600125
- anthra(1,9-cd)pyrazol-6(2H)-one
- TNF-α
- tumor necrosis factor-α
- TGF-β
- transforming growth factor-β
- U0126
- 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene
- XTT
- sodium 3′-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis (4-methoxy-6-nitro) benzene sulfonic acid hydrate
- z-VAD-FMK
- Z-Val-Ala-Asp(OMe)-CH2F.
- Received December 2, 2011.
- Accepted July 3, 2012.
- Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|